BIOKIN PHARMACEUTICAL(SH:688506) Shang Hai Zheng Quan Bao·2025-09-18 19:52Fundraising Overview - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has successfully raised a total of RMB 3,763,999,989.00 by issuing 11,873,817 shares at a price of RMB 317.00 per share, with a net amount of RMB 3,731,054,180.03 after deducting issuance costs [1][2] Fund Management and Regulatory Agreement - The company has established a special account for the management of the raised funds, ensuring that the funds are stored and used specifically for the innovation drug research and development projects [3][4] - A tripartite regulatory agreement has been signed among the company, China Construction Bank Chengdu Eighth Branch, and CITIC Securities, which outlines the management and usage of the raised funds [2][3] Key Provisions of the Agreement - The special account is exclusively for the storage and use of the raised funds, prohibiting any non-raising funds or alternative uses [3] - The company can invest temporarily idle funds in cash management products, provided it complies with relevant regulations and informs the sponsor [3][4] - The sponsor is responsible for ongoing supervision of the fund management and usage, with the authority to conduct investigations and request information from the bank [4][5] Reporting and Compliance - The bank is required to provide monthly account statements to the company and the sponsor, ensuring transparency in fund management [5][6] - Any withdrawals exceeding RMB 50 million or 20% of the net amount must be reported to the sponsor within five working days [5][6] - The agreement remains effective until all funds are fully utilized and the sponsor's supervision period concludes [6]